Mycophenolate Mofetil Tablets Under Fasting Conditions

NCT ID: NCT00907907

Last Updated: 2024-08-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-07-31
• Study Completion Date: 2006-08-31

Brief Summary

The objective of this study was to evaluate the comparative bioavailability between Mycophenolate Mofetil 500 mg Tablets (test) and CellCept® 500 mg tablets (reference), after a single-dose in healthy subjects under fasting conditions.

Detailed Description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Mycophenolate Mofetil (test) First

Mycophenolate Mofetil Tablets, 500 mg dosed in first period followed by CellCept® Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.

Group Type: EXPERIMENTAL

Mycophenolate Mofetil

Intervention Type: DRUG

Mycophenolate Mofetil Tablet 500 mg

Cellcept® (reference) First

CellCept® Tablets, 500 mg dosed in first period followed by Mycophenolate Mofetil Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.

Group Type: ACTIVE_COMPARATOR

CellCept® Tablets

Intervention Type: DRUG

CellCept® Tablets, 500 mg

Interventions

Mycophenolate Mofetil

Mycophenolate Mofetil Tablet 500 mg

Intervention Type: DRUG

CellCept® Tablets

CellCept® Tablets, 500 mg

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy, non-smoking male subjects, 18 years of age or older.
• Healthy, non-smoking post-menopausal or surgically sterile females 18 years of age or older.
• BMI ≥ 19 and ≤ 30.
• Negative for:

1. HIV.

2. Hepatitis B surface antigen and Hepatitis C antibody.

3. Using drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone).

4. Urine cotinine test

5. Serum HCG consistent with pregnancy (females only)

• No significant diseases or clinically significant findings in a physical examination.
• No clinically significant abnormal laboratory values.
• No clinically significant findings in vital signs measurements and a 12-lead electrocardiogram (ECG).
• Be informed of the nature of the study and given written consent prior to receiving any study procedure.
• Females who participate in this study must be unable to have children:

1. post-menopausal for at least 1 year - no menstrual cycle for 12 months and LH and FSH levels judged by a physician to be consistent with post-menopausal status.

OR

2. Proof of surgical sterility.

• Females who participate in this study are not pregnant and/or non-lactating.

Exclusion Criteria

• Known history or presence of any clinically significant medical condition.
• Known or suspected carcinoma.
• Known or suspected increased susceptibility to infection.
• Known history or presence of active tuberculosis (TB).
• Results of a previous TB skin test greater than 5 mm in diameter.
• Lived in or traveled, during the last 8 weeks, to a country defined by the Public Health Agency of Canada as having WHO estimated sputum smear positive pulmonary TB rate of 15 per 100,000 or higher.
• Known history or presence of:

1. Hypersensitivity or idiosyncratic reaction to mycophenolate mofetil and/or any other drug substances with similar activity.

2. Alcoholism within the last 12 months.

3. Drug dependence and/or substance abuse.

4. Use of tobacco or nicotine-containing products within the last 6 months.

• On a special diet within 4 weeks prior to drug administration (e.g. liquid, protein, raw food diet).
• Participated in another clinical trial or received and investigational product within 30 days prior to drug administration.
• Donated up to 250 mL of blood within the previous 30 days OR Donated from 251 to 499 mL of blood in the previous 45 days OR Donated more than 499 mL of blood in the previous 56 days (based on the Canadian Blood Services guideline for blood donation.
• Females taking oral or transdermal hormonal contraceptives within 14 days preceding period 1 dosing.
• Females having taken implanted or injected hormonal contraceptives within 6 months prior to period 1 dosing.
• Requirement of any non-topical medication (prescription and/or over-the-counter) on a routine basis.
• Difficulty fasting or consuming the standard meals.
• Do not tolerate venipuncture.
• Unable to read or sign the ICF.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Teva Pharmaceuticals USA

INDUSTRY

Sponsor Role: lead

Principal Investigators

Xueyu (Eric) Chen, MD, Ph.D., FRCP(C)

Role: PRINCIPAL_INVESTIGATOR

Pharma Medica Research, Inc.

Locations

Pharma Medica Research Inc.

Toronto, Ontario, Canada

Countries

Canada

Other Identifiers

2006-1263

Identifier Type: -

Identifier Source: org_study_id